Sistemic short-listed as a top 10 “company to watch” in the stem cell field and announce the initiation of the development of a ground-breaking range of products for cell therapy product characterisation

Release Date: October 7, 2014

 

Glasgow, Scotland Sistemic Ltd announced today that the company had been short-listed as one of the top 10 companies to watch in the developing stem cell sector by the well regarded digest StemCellAssays.

With the development of social media, sites like SCA have become popular for information dissemination and SCA was awarded the Stem Cell Blog of the year award in 2012. The judges stated that they considered the site “a must read for those interested in stem cells, particularly in the clinical applications field”. Additionally the company has announced that it will embark on the development of a number of ground-breaking products for the cell therapy industry which will enhance the development of exciting products in this sector. The stem cell industry holds great promise for the potential treatment of many major human diseases in the fields of cancer, neurology, cardiology, autoimmunity and inflammation. Sistemic hope that by developing their miRNA technology for the characterisation of stem cell into easy to use products the industry will receive a huge boost towards making cell therapy products more widely available.

Jim Reid, CEO of Sistemic said “It is always nice to be nominated by someone independent but the wide readership means that Sistemic is being discussed by many people we would not be able to reach. Additionally, the quality of the site and the unbiased nature gives real weight to the fact that we are providing a unique set of technologies to the stem cell industry.” Commenting on the announcement of the company’s move into product development Reid added “it is a significant step forward for Sistemic but it is essential for the development of the stem cell industry that easy to use products become available to test the quality of products as they move into production and start to be released for treatment. Sistemic is leading the field in the development of easy to use characterisation and QC tools and now sees the need within the industry to move its technology towards products which can be used at the point of production.”

Sistemic Ltd

Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets.
MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. Furthermore, cell products in the later stages of clinical development benefit from SistemQC™ miRNA-based profiling approach in facilitating patient stratification and monitoring the response to the treatment. In addition, the drug development markets are served through a range of products which include SistemTOX™ , SistemKB™ and SistemRNA™ . Sistemic has a worldwide customer base and a strong intellectual property portfolio.

For more information contact: press@sistemic.co.uk